Abstracts Archive - Page 1355 of 2607 - ACR Meeting Abstracts

Abstract Number: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Sadettin Uslu¹, Gerçek Can¹, Soner Senel², Ediz Dalkiliç³, Nevsun Inanc⁴, Servet Akar⁵, Sinem Burcu Kocaer¹, Merih Birlik¹, Sedat Capar⁶, Nurullah Akkoc⁷ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ³Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁶Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁷Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.The…
Abstract Number: 2533 • 2018 ACR/ARHP Annual Meeting
Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study
Anastasia- Vasiliki Madenidou¹, Andrew Jeffries², Sneha Varughese², Stephen Jones², Helen Veevers², Hanadi Sari- Kouzel² and Chandini Rao², ¹Rheumatology, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom, ²Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel.In 2016, the Rheumatology Department at Blackpool…
Abstract Number: 2534 • 2018 ACR/ARHP Annual Meeting
Impact of Block Switch to Biosimilar Etanercept in Practice, Accross Different Rheumatic Diseases
Luisa Brites¹, Flavio Costa², João Freitas³, Mariana Luis⁴, Margarida Coutinho⁴, Mariana Santiago³, Cátia Duarte⁵, Maria Joao Salvador⁴ and José António P. da Silva⁶, ¹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ²Rheumatology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ³Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, ⁴Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁵Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁶Department of rheumatology, Centro Hospitalar e Universitário de Coimbra (SRHUC), Coimbra, Portugal
Background/Purpose: Biosimilars of biotechnological agents represent an important opportunity to increase accessibility to these medications. Clinicians still maintain reservations regarding the similarity of their efficacy…
Abstract Number: 2535 • 2018 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers
Yujeong Shim¹, Seieun Kim¹, Maria Velinova², Gerhard Arold³, Semi Kim⁴, Young Il Choi⁴ and Kyung Mi Park⁵, ¹Product Development, Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea, Republic of (South), ²PRA Health Sciences, Zuidlaren, Netherlands, ³PRA Health Sciences, Berlin, Germany, ⁴Research Institute of Chong Kun Dang Pharmaceutical Corporation, Yongin, Korea, Republic of (South), ⁵Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea, Republic of (South)
Background/Purpose: HDAC6 is a pleiotropic enzyme which removes of acetyl groups from non-histone proteins. HDAC6 inhibition represses inflammatory responses such as cytokines, chemokines and cell…
Abstract Number: 2536 • 2018 ACR/ARHP Annual Meeting
Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy
Frieda A. Koopman¹, Anne Musters², Marieke M.J. Backer², Danielle Gerlag², Sanda Miljko³, Simeon Grazio⁴, Sekib Sokolovic⁵, Yaakov Levine⁶, David Chernoff⁶, Niek de Vries⁷ and Paul-Peter Tak², ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³University Clinical Hospital, Mostar, Bosnia, ⁴Vinogradsira 29, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ⁵Rheumatology, Sarajevo University Clinical Center, Sarajevo, BA, ⁶SetPoint Medical, Inc., Valencia, CA, ⁷Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: RA is a debilitating chronic disease with an unmet need for additional therapeutic approaches. Modulating innate neuro-immune reflex pathways by stimulation of the vagus…
Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Klaus Krüger¹, Carlo Selmi^2,3, Alain Cantagrel⁴, Miguel A. Abad⁵, Ulrich Freudensprung⁶, Mourad Farouk Rezk⁶ and Janet Addison⁷, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy, ⁴Center of Rheumatology of CHU, Toulouse, France, ⁵FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁶Biogen International GmbH, Zug, Switzerland, ⁷Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 2538 • 2018 ACR/ARHP Annual Meeting
Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis
Min Chen¹, Xiao-Feng Li², Chong Gao³ and Cai-Hong Wang⁴, ¹The Second Hospital of Shanxi Medical Univerity, Taiyuan City, China, ²Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ³Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁴The Second Hospital of Shanxi Medical Univerity, Taiyuan, China
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints.We found that there was an imbalance between Th17 and Treg…
Abstract Number: 2539 • 2018 ACR/ARHP Annual Meeting
SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
Diederik De Cock¹, Lianne Kearsley-Fleet², Rebecca Davies², Kath Watson² and Kimme L. Hyrich^1,3, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In the United Kingdom (UK) since 2016, etanercept biosimilars (SB4) are since 2016 a first-line treatment option for the management of severe rheumatoid arthritis…
Abstract Number: 2540 • 2018 ACR/ARHP Annual Meeting
Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Xavier Mariette¹, Elodie Perrodeau², Christian Verner³, Xavier Struillou⁴, Thierry Schaeverbeke⁵, Alain Cantagrel⁶, Philippe Ravaud⁷ and Philippe Bouchard⁸, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Paris Hotel Dieu, Paris, France, ³Periodontology, UFR d'odontologie, University of Nantes, Nantes, France, ⁴Periodontology, UFR d'odontologie, University of Nantes,, Nantes, France, ⁵Rheumatology, CHU Bordeaux, Bordeaux, France, ⁶Rheumatology, CHU Toulouse, Toulouse, France, ⁷INSERM UMR1153, Paris Descartes University, Paris, France, ⁸Paris Diderot University, Paris, France
Background/Purpose: Good evidence suggests a relationship between rheumatoid arthritis (RA) and periodontitis. We aimed to investigate if a good oral hygiene could improve activity of…
Abstract Number: 2541 • 2018 ACR/ARHP Annual Meeting
Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards
Ronald van Vollenhoven¹, Robin K. Dore², Kun Chen³, Heidi S. Camp³, Jose Jeffrey Enejosa³, Tim Shaw³, Jessica Suboticki³ and Stephen Hall⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Univ of California, Los Angeles, CA, ³AbbVie Inc., North Chicago, IL, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia
Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor, demonstrated efficacy through 12 and 24 weeks (wks) in phase 3 trials of patients (pts) with active rheumatoid…
Abstract Number: 2542 • 2018 ACR/ARHP Annual Meeting
Integrated Exposure-Response Analyses for Upadacitinib Efficacy and Effects on Laboratory Parameters in Rheumatoid Arthritis – Analyses of Phase 2b Studies
Mohamed-Eslam Mohamed¹, Insa Winzenborg², Eva Doelger², Peter Noertersheuser³, Heidi S. Camp¹, Sebastian Meerwein³ and Ahmed A. Othman¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Upadacitinib is an oral, selective inhibitor of Janus kinase 1 (JAK1) which is currently being evaluated for the treatment of several autoimmune disorders, including…
Abstract Number: 2543 • 2018 ACR/ARHP Annual Meeting
Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Hyoun-Ah Kim¹, Eun-Young Lee², Sun Kyung Lee³, Yong-Beom Park⁴, Young Nam Lee⁵, HeeJung Kang⁶ and Kichul Shin⁷, ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Department of Medical Informatics, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁵Celltrion Healthcare Co. Ltd, Incheon, Korea, Republic of (South), ⁶Celltrion Healthcare Co.Ltd, Incheon, Korea, Republic of (South), ⁷Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: CT-P13 is a biosimilar prescribed in a number of countries for indications approved for the reference infliximab (RINF) including rheumatoid arthritis (RA), ankylosing spondylitis…
Abstract Number: 2544 • 2018 ACR/ARHP Annual Meeting
Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy
Xiaoxia Jia¹, Fang Li², Jing Luo³, Chong Gao⁴ and Xiao-Feng Li¹, ¹Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ³the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Recent studies have showed that quantitative and/or functional abnormalities of the regulatory T cells (Tregs) may play a vital role in the development of…
Abstract Number: 2545 • 2018 ACR/ARHP Annual Meeting
Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)
Ashley Fletcher^1,2, Margaret P. Staples^3,4, Catherine Hill^5,6,7, Marissa Lassere⁸, Lyn March^9,10,11,12, Graeme Carroll¹³, Claire Barrett¹⁴, Vibhasha Chand⁴ and Rachelle Buchbinder^4,15, ¹Monash Department of Clinical Epidemiology, Cabrini Institute, Melbourne, Australia, ²Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Monash Department of Clinical Epidemiology, Cabrini Institute, Malvern, Australia, ⁴Monash University, Melbourne, Australia, ⁵The Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia, ⁸University of New South Wales, Sydney, Australia, ⁹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁰Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, ¹¹Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹²Rheumatology, University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, ¹³Adult Rheumatology and Osteoarthritis, University of Notre Dame, Mount Lawley WA, Australia, ¹⁴Redcliffe Hospital, University of Queensland, Redcliffe, Australia, ¹⁵Cabrini Institute, Victoria, Australia
Background/Purpose: To describe the use of oral complementary medicine (CM) in people with inflammatory arthritis. Methods: The Australian Rheumatology Association Database (ARAD), an observational database,…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].